###begin article-title 0
###xml 135 139 <span type="species:ncbi:10090">mice</span>
Distinct expression of synaptic NR2A and NR2B in the central nervous system and impaired morphine tolerance and physical dependence in mice deficient in postsynaptic density-93 protein
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 168 176 168 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 768 772 <span type="species:ncbi:10090">mice</span>
###xml 892 896 <span type="species:ncbi:10090">mice</span>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
###xml 973 977 <span type="species:ncbi:10090">mice</span>
###xml 1238 1242 <span type="species:ncbi:10090">mice</span>
###xml 1485 1489 <span type="species:ncbi:10090">mice</span>
Postsynaptic density (PSD)-93, a neuronal scaffolding protein, binds to and clusters N-methyl-D-aspartate receptor (NMDAR) subunits NR2A and NR2B at cellular membranes in vitro. However, the roles of PSD-93 in synaptic NR2A and NR2B targeting in the central nervous system and NMDAR-dependent physiologic and pathologic processes are still unclear. We report here that PSD-93 deficiency significantly decreased the amount of NR2A and NR2B in the synaptosomal membrane fractions derived from spinal cord dorsal horn and forebrain cortex but did not change their levels in the total soluble fraction from either region. However, PSD-93 deficiency did not markedly change the amounts of NR2A and NR2B in either synaptosomal or total soluble fractions from cerebellum. In mice deficient in PSD-93, morphine dose-dependent curve failed to shift significantly rightward as it did in wild type (WT) mice after acute and chronic morphine challenge. Unlike WT mice, PSD-93 knockout mice also showed marked losses of NMDAR-dependent morphine analgesic tolerance and associated abnormal sensitivity in response to mechanical, noxious thermal, and formalin-induced inflammatory stimuli after repeated morphine injection. In addition, PSD-93 knockout mice displayed dramatic loss of jumping activity, a typical NMDAR-mediated morphine withdrawal abstinence behavior. These findings indicate that impaired NMDAR-dependent neuronal plasticity following repeated morphine injection in PSD-93 knockout mice is attributed to PSD-93 deletion-induced alterations of synaptic NR2A and NR2B expression in dorsal horn and forebrain cortex neurons. The selective effect of PSD-93 deletion on synaptic NMDAR expression in these two major pain-related regions might provide the better strategies for the prevention and treatment of opioid tolerance and physical dependence.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 818 819 818 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 820 821 820 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Opioid drugs such as morphine are a class of powerful analgesics used for treating many forms of acute and chronic pain. However, their chronic use has been limited by undesirable side effects such as tolerance, abnormal pain sensitivity, and physical dependence [1,2]. These undesirable symptoms are believed to be related to neuronal plasticity in the central nervous system (CNS). Several lines of research have shed light on molecular and cellular mechanisms that underlie the development of opioid analgesic tolerance and dependence [3-5]. Pharmacological blockade of NMDA receptors (NMDARs) or targeted disruption of NMDAR subunit NR2 genes significantly attenuates symptoms of opioid tolerance and physical dependence, implicating involvement of NMDARs in the development of opioid-induced neuronal plasticity [6-8]. However, the molecular mechanisms underlying NMDAR-dependent synaptic plasticity during the development of opioid tolerance and physical dependence are unclear.
###end p 4
###begin p 5
###xml 5 6 5 6 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 10 11 10 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">s</underline>
###xml 19 20 19 20 <underline xmlns:xlink="http://www.w3.org/1999/xlink">d</underline>
###xml 52 54 52 54 <underline xmlns:xlink="http://www.w3.org/1999/xlink">ch</underline>
###xml 60 61 60 61 <underline xmlns:xlink="http://www.w3.org/1999/xlink">a</underline>
###xml 71 72 71 72 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 82 85 82 85 <underline xmlns:xlink="http://www.w3.org/1999/xlink">syn</underline>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 358 359 358 359 <underline xmlns:xlink="http://www.w3.org/1999/xlink">s</underline>
###xml 366 367 366 367 <underline xmlns:xlink="http://www.w3.org/1999/xlink">a</underline>
###xml 377 378 377 378 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1152 1161 1152 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1162 1164 1162 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1334 1336 1334 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1481 1483 1481 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 859 864 <span type="species:ncbi:4932">yeast</span>
###xml 1398 1402 <span type="species:ncbi:10090">mice</span>
PSD (post synaptic density)-93, also named chapsyn (channel-associated protein of synapses)-110, is one of a growing superfamily of PDZ-domain-containing proteins shown to physically link proteins together into macromolecular structures [9,10]. PSD-93 was identified to have structural similarity with three other PDZ-domain-containing proteins, PSD-95/SAP (synapse-associated protein) 90 [11,12], SAP102 [12,13], and SAP97/hdlg [14,15]. These proteins are generically referred to as membrane-associated guanylate kinases (MAGUKs) and contain three tandem PDZ domains (PDZ1-3) at the N-terminal side, an Src homology region 3 domain in the middle, and a guanylate kinase-like domain at the C-terminal end. PDZ domains of MAGUKs are motifs of ~90 amino acid repeats that have recently been recognized to mediate protein-protein interactions. Studies using the yeast two-hybrid system revealed that the PDZ domains of PSD-93 specifically bind to the C-termini of NMDAR subunits NR2A and NR2B [10]. The deletion of PDZ domains from PSD-93 not only disrupts interaction between NR2A/NR2B and PSD-93, but also reduces NMDAR clustering at cellular membranes in vitro [10]. Targeted disruption of the PSD-93 gene reduces NMDAR-mediated postsynaptic function in dorsal horn and forebrain cortex and attenuated NMDAR-mediated persistent pain [16]. However, a recent study reported that PSD-93 knockout (KO) mice displayed normal NMDAR-mediated postsynaptic response in hippocampal neurons [17]. It appears that the roles of PSD-93 in synaptic NMDAR targeting and NMDAR-dependent physiologic and pathologic processes in the CNS are still unclear.
###end p 5
###begin p 6
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
In the present study, we examined whether PSD-93 deficiency affected synaptic NR2A and NR2B expression in two major pain-related regions [18,19], spinal cord and forebrain cortex, and a motor and coordination-related region [20], cerebellum, of the CNS. Furthermore, we examined whether PSD-93 was required for NMDAR-dependent development of neuronal plasticity during morphine tolerance and physical dependence.
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin title 8
Animals
###end title 8
###begin p 9
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
The PSD-93 KO mice (C57BL/6 genetic background) were generated as described previously [21]. Male PSD-93 KO mice and wild type (WT) littermates (10-12 weeks) were obtained by interbreeding PSD-93 heterozygous mice. All animal experiments were carried out with the approval of the Animal Care and Use Committee at Johns Hopkins University. The experimenter was blind to the genotype of the mice in all studies.
###end p 9
###begin title 10
Tail-flick assay
###end title 10
###begin p 11
A tail-flick apparatus (Model 33B Tail Flick Analgesy Meter, IITC Life Science, Woodland Hills, CA, USA) with a radiant heat source connected to an automatic timer was used to assess the analgesic response. A cut-off time latency of 10 s was used to avoid tissue damage to the tail. Tail-flick latencies were measured as the time required to induce a tail flick after applying radiant heat to the skin of the tail. The antinociceptive effects were expressed as the percentage of maximal possible analgesic effect (% MPAE): % MPAE = [(response latency - baseline latency)/(cut-off latency - baseline latency)] x 100%.
###end p 11
###begin title 12
Morphine-induced tolerance studies
###end title 12
###begin p 13
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 562 566 <span type="species:ncbi:10090">Mice</span>
###xml 682 686 <span type="species:ncbi:10090">Mice</span>
###xml 883 887 <span type="species:ncbi:10090">mice</span>
Acute morphine tolerance was induced by two subcutaneous (s.c.) injections of 100 mg/kg morphine (WT: n = 10; KO: n = 10) or saline (control; WT: n = 10; KO: n = 10) given 12 h apart [22,23]; chronic morphine tolerance was induced by s.c. injections of morphine (10 mg/kg) (WT: n = 10; KO: n = 10) or saline (control; WT: n = 10; KO: n = 10) given every 12 h for 6 days [8]. On day 2 after induction of acute morphine tolerance or day 7 after induction of chronic morphine tolerance, cumulative dose-response curves were determined as described previously [24]. Mice received a very low morphine dose (1 mg/kg, s.c.) and analgesia was assessed 30 min later by the tail-flick assay. Mice that were not analgesic at the first dose then received a second dose (cumulative dosing increase by a 0.3 log unit) and were tested 30 min afterward. This procedure was repeated until either the mice did not move their tail within the cut-off time or no further increase in tail-flick latency was noted from one dose to the next.
###end p 13
###begin p 14
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
To observe whether repeated morphine injection produced a time-dependent and NMDAR-dependent reduction in morphine analgesic effects, WT and KO mice received s.c. injections of morphine (10 mg/kg) or saline twice daily (12-h intervals) with intraperitoneal (i.p.) injection of saline or 0.3 mg/kg MK-801 once daily for 6 days. WT and KO mice were divided into four paired groups (n = 10 WT and 10 KO per group): s.c. saline + i.p. saline, s.c. morphine + i.p. saline, s.c. saline + i.p. MK-801, and s.c. morphine + i.p. MK-801. Tail-flick latencies were determined prior to drug injection and 1 h after the first injection of morphine on days 1, 3, 5, and 7.
###end p 14
###begin title 15
Morphine-induced abnormal pain hypersensitivity studies
###end title 15
###begin p 16
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 184 188 <span type="species:ncbi:10090">Mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 665 670 <span type="species:ncbi:10090">mouse</span>
To determine whether NMDAR-dependent mechanical allodynia occurs in morphine-tolerant mice, paw withdrawal response to mechanical stimuli was measured as described previously [16,25]. Mice received s.c. injections of morphine (20 mg/kg) or saline twice daily with i.p. injection of 0.3 mg/kg MK-801 or saline once daily for 6 days. WT and KO mice were divided into four paired groups (n = 6 WT and 6 KO per group): s.c. saline + i.p. saline, s.c. morphine + i.p. saline, s.c. saline + i.p. MK-801, and s.c. morphine + i.p. MK-801. Mechanical behavioral testing was performed before drug injection (baseline) and on days 1, 2, and, 4 after morphine withdrawal. Each mouse was placed in a Plexiglas chamber on an elevated mesh screen. Two calibrated von Frey filaments (0.24 and 1.47 mN; Stoelting Co., Wood Dale, IL, USA) were applied to the hind paw for approximately 1 s, and each stimulation was repeated 10 times to both hind paws. The occurrence of paw withdrawal in each of these 10 trials was expressed as a percent response frequency [(number of paw withdrawals/10 trials) x 100 = % response frequency], and this percentage was used as an indication of the amount of paw withdrawal.
###end p 16
###begin p 17
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 472 476 <span type="species:ncbi:10090">Mice</span>
To determine whether NMDAR-dependent thermal hyperalgesia occurs in morphine-tolerant mice, paw withdrawal response to noxious heat stimulation was measured as described previously [16,25]. WT (n = 24) and KO (n = 24) mice were divided into four paired groups and given drug treatments according to the same protocol as for the mechanical test. Thermal behavioral testing was carried out before drug injection (baseline) and on days 1, 2, and 4 after morphine withdrawal. Mice were placed in a Plexiglas chamber on a glass plate. A radiant heat from Model 336 Analgesic Meter (IITC Inc./Life Science Instruments, Woodland Hills, CA, USA) was applied by aiming a beam of light through a hole in the light box through the glass plate to the middle of the plantar surface of each hind paw. When the animal lifted its foot, the light beam was turned off. The length of time between the start of the light beam and the foot lift was defined as the paw withdrawal latency. Each trial was repeated five times at 5-min intervals for each side. A cut-off time of 20 s was used to avoid tissue damage to the hind paw.
###end p 17
###begin p 18
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
The formalin test was performed as described previously [26]. Briefly, mice received s.c. injection of morphine (20 mg/kg) or saline twice daily for 6 days. On day 7, WT (n = 12; 6 for saline and 6 morphine) and KO (n = 12) mice received a 10-mul intraplantar injection of 1% formalin. After the formalin injection, the duration of paw licking was recorded in 5-min periods for 60 min. We defined the first phase response as the total time spent licking during the first 10 min and the second phase response as the duration of licking that occurred 10-60 min after formalin injection.
###end p 18
###begin title 19
Naloxone-precipitated withdrawal symptoms
###end title 19
###begin p 20
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 613 618 <span type="species:ncbi:10090">mouse</span>
Among naloxone-precipitated withdrawal symptoms, jumping is reliably observed in mice, although other symptoms, such as forepaw tremor and rearing, are sometimes observed [27]. To examine an NMDAR-dependent morphine physical dependence, the number of jumps was analyzed quantitatively. Briefly, WT and KO mice (10/genotype/treatment) were injected twice daily with morphine (10 mg/kg, i.p.) and once daily with 0.3 mg/kg MK-801 or saline for 6 days and on the seventh day challenged with naloxone (2 mg/kg, i.p.) 2 h after a final s.c. injection of morphine (10 mg/kg). Immediately after naloxone treatment, each mouse was placed into a transparent acrylic quadribox (20 x 30 cm), and jump frequency was tallied over the next 15 min.
###end p 20
###begin title 21
Subcellular fractionation of proteins
###end title 21
###begin p 22
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 564 566 564 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 894 896 888 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 1025 1027 1019 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 1123 1125 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1126 1128 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
Biochemical fractionation was carried out according to previous studies with minor modification [28,29]. WT (n = 12) and KO (n = 12) mice were sacrificed and lumbar enlargement spinal cord, forebrain cortex, and cerebellum collected. The dorsal part of the spinal cord was separated from the ventral part. The tissues were homogenized in homogenization buffer [10 mM Tris-HCl (pH 7.4), 5 mM NaF, 1 mM sodium orthovanadate, 320 mM sucrose, 1 mM EDTA, 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, and 2 mM pepstatin A] and centrifuged at 1,000 x g for 20 min at 4degreesC. The supernatant (S1, total soluble fraction) was collected and the pellet (P1, nuclei and debris fraction) discarded. After measurement of the protein concentration, 20% of S1 was removed for detecting protein expression in the total soluble fraction. The remaining S1 (80%) was centrifuged at 10,000 x g for 20 min to produce a pellet (P2) and supernatant (S2). The P2 was lysed hypo-osmotically in water and centrifuged at 25,000 x g to produce pellet 3 (P3). The P3 was considered to be the crude synaptosomal membrane fraction [28,29].
###end p 22
###begin title 23
Western blot analysis
###end title 23
###begin p 24
###xml 389 390 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 642 643 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 310 316 <span type="species:ncbi:9986">rabbit</span>
###xml 377 383 <span type="species:ncbi:9986">rabbit</span>
###xml 443 449 <span type="species:ncbi:9986">rabbit</span>
###xml 502 508 <span type="species:ncbi:9986">rabbit</span>
###xml 560 565 <span type="species:ncbi:10090">mouse</span>
###xml 841 847 <span type="species:ncbi:9986">rabbit</span>
###xml 856 861 <span type="species:ncbi:10090">mouse</span>
The samples were heated for 5 min at 99degreesC and then loaded onto 4% stacking/7.5% separating SDS-polyacrylamide gels. The proteins were eletrophoretically transferred onto nitrocellulose membrane. The blotting membrane was blocked with 3% non-fat dry milk for 1 h and incubated overnight at 4degreesC with rabbit anti-PSD-93 (1:1,000; Alomone Labs Ltd, Jerusalem, Israel), rabbit anti-N-cadherin (1: 1,000; BD Biosciences, Palo Alto, CA), rabbit anti-NR2A (1: 200, Upstate/CHEMICON, Temecula, CA), rabbit anti-NR2B (1:500, Upstate/CHEMICON), or monoclonal mouse anti-beta-actin (1:10,000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). N-cadherin was used as a loading control and marker for crude synaptosomal fraction, whereas beta-actin was used as a loading control for total soluble fraction. The proteins were detected with anti-rabbit or anti-mouse secondary antibody and visualized with the chemiluminescence reagents provided with the ECL kit (Amersham Pharmacia Biotech, Piscataway, NJ) and exposure to film. The intensity of blots was quantified with densitometry. The blot density from naive animals was set as 100%.
###end p 24
###begin title 25
Statistical analysis
###end title 25
###begin p 26
###xml 111 113 109 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 333 335 331 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 447 449 445 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Data are expressed as mean +/- SEM. The effective dose that resulted in a 50% reduction of control response (ED50) and 95% confidence intervals (CIs) were calculated by using a least-squares linear regression method according to the formulae given by Tallarida and Murray (1987). Statistical significance was determined by student's t tests or one-way and two-way analysis of variance followed by the post hoc Tukey tests. Significance was set at P < 0.05. The statistical software package SigmaStat (Systat, Port Richard, CA) was used to perform all statistical analyses.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
3.1. Effect of PSD-93 deletion on the expression of NR2A and NR2B in total soluble and synaptosomal membrane fractions
###end title 28
###begin p 29
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 525 527 525 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 544 546 544 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 675 677 675 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 694 696 694 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 818 820 818 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 838 840 838 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 467 471 <span type="species:ncbi:10090">mice</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
###xml 743 747 <span type="species:ncbi:10090">mice</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
###xml 878 882 <span type="species:ncbi:10090">mice</span>
Immunoblot analysis showed that PSD-93 deletion did not alter expression of NR2A and NR2B in total soluble fractions from dorsal horn, forebrain cortex, or cerebellum of mice (Fig. 1A), a finding consistent with those in previous studies [16,21,30]. However, PSD-93 deletion significantly reduced the levels of NR2A and NR2B in the synaptosomal membrane fractions from dorsal horn and forebrain cortex, but not cerebellum, of mice (Fig. 1B). In the dorsal horn of KO mice, the amounts of NR2A and NR2B were decreased by 55% (P < 0.01) and 56% (P < 0.01), respectively, compared to those in WT mice. In the cortex of KO mice, the amounts of NR2A and NR2B were reduced by 60% (P < 0.01) and 58% (P < 0.01), respectively, compared to those in WT mice. In the cerebellum of KO mice, the levels of NR2A and NR2B were 103% (P > 0.05) and 104% (P > 0.05), respectively, of those in WT mice.
###end p 29
###begin p 30
###xml 0 188 0 188 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of NR2A and NR2B in total soluble (A) and synaptosomal membrane (B) fractions from dorsal horn, forebrain cortex, and cerebellum in wild type (WT) and PSD-93 knockout (KO) mice.</bold>
###xml 669 670 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 684 686 681 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 693 696 690 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 723 727 <span type="species:ncbi:10090">mice</span>
Expression of NR2A and NR2B in total soluble (A) and synaptosomal membrane (B) fractions from dorsal horn, forebrain cortex, and cerebellum in wild type (WT) and PSD-93 knockout (KO) mice. (A) Top: representative Western blots showing the levels of PSD-93, NR2A, and NR2B in the total soluble fraction. Bottom: statistical summary of the densitometric analysis expressed relative to the corresponding loading control (beta-actin). (B) Top: representative Western blots showing the amounts of PSD-93, NR2A, and NR2B in the synaptosomal membrane fraction. Bottom: statistical summary of the densitometric analysis expressed relative to the corresponding loading control (N-cadherin). **P < 0.01 vs the corresponding naive WT mice.
###end p 30
###begin title 31
3.2. Effect of PSD-93 deletion on acute and chronic morphine tolerance
###end title 31
###begin p 32
###xml 176 178 172 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 233 236 229 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 289 291 285 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 378 380 374 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 536 538 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 543 545 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 686 688 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
###xml 675 679 <span type="species:ncbi:10090">mice</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
We first examined the role of PSD-93 in acute morphine tolerance. Baseline tail-flick latencies were similar in KO (4.84 +/- 0.26; n = 19) and WT (4.40 +/- 0.20; n = 20) mice (P > 0.05). In the control (saline-treated) groups, the ED50 of the dose-response curve of morphine in KO mice (ED50: 2.32 mg/kg; 95% CI: 1.89-2.99 mg/kg) was significantly lower than that in WT mice (ED50: 3.75 mg/kg; 95% CI: 2.87-5.43 mg/kg), although the analgesic effect induced by the first dose of morphine in KO mice was similar to that in WT mice (Fig. 2A and 2B). After acute morphine challenge, the morphine dose-response curve was shifted significantly to the right in the WT, but not KO, mice (Fig. 2A). The morphine ED50 value (and 95% CI) was 6.08 mg/kg (5.29-7.15 mg/kg) in the WT mice and 2.40 mg/kg (2.29-2.52 mg/kg) in the KO mice.
###end p 32
###begin p 33
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of targeted disruption of PSD-93 gene on morphine analgesic tolerance.</bold>
###xml 863 865 863 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 872 875 872 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 704 708 <span type="species:ncbi:10090">mice</span>
Effect of targeted disruption of PSD-93 gene on morphine analgesic tolerance. (A) The cumulative dose-response curves of morphine in WT and PSD-93 KO mice following acute morphine (M) analgesic tolerance induced by two subcutaneous injections of morphine (100 mg/kg, 12 h apart). Control groups received saline (S) injection on the same schedule. (B) The cumulative dose-response curves of morphine in WT and PSD-93 KO mice following chronic morphine analgesic tolerance induced by subcutaneous injections of morphine (10 mg/kg) twice daily for 6 days. Control groups received saline injections on the same schedule. (C) Time course of morphine-induced analgesia and effect of MK-801 in WT and PSD-93 KO mice following subcutaneous injections of 10 mg/kg morphine twice daily plus intraperitoneal injection of saline or 0.3 mg/kg MK-801 once daily for 6 days. ** P < 0.01 vs the corresponding value on day 1.
###end p 33
###begin p 34
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 221 224 221 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 741 743 741 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 759 761 759 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 781 783 781 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 1117 1119 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
###xml 888 892 <span type="species:ncbi:10090">mice</span>
###xml 1051 1055 <span type="species:ncbi:10090">mice</span>
###xml 1250 1254 <span type="species:ncbi:10090">mice</span>
We then investigated the effect of PSD-93 deletion on chronic morphine tolerance. Chronic morphine challenge produced a rightward shift in the morphine dose-response curve in both WT and KO mice (Fig. 2B). However, the ED50 of the dose-response curve of morphine in KO mice was significantly smaller than that in WT mice (Fig. 2B). The morphine ED50 value (and 95% CI) was 8.92 mg/kg (7.47-11.08 mg/kg) in the WT mice and 3.55 mg/kg (2.05-13.05 mg/kg) in the KO mice. Chronic morphine challenge also produced a time-dependent reduction in morphine analgesic effects in the WT, but not KO, mice (Fig. 2C). In the WT mice that received repeated injections of s.c morphine plus i.p. saline, the MPAEs on days 3, 5, and 7 were reduced by 18.9% (P > 0.05), 38.3% (P < 0.01), and 60.2% (P < 0.01), respectively, from the value on day 1 (100%). These reductions were markedly reversed in the WT mice that received i.p. MK-801 rather than saline (Fig. 2C). In contrast, no significant changes in the MPAEs were observed among these four time points in the KO mice that received s.c. morphine plus i.p. saline or MK-801 (Fig. 2C). In addition, repeated injections of i.p. MK-801 at the dose used did not affect basal tail-flick latency in either the WT or KO mice that received s.c saline (data not shown).
###end p 34
###begin title 35
3.3. Effect of PSD-93 deletion on morphine-induced abnormal pain hypersensitivity
###end title 35
###begin p 36
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 281 283 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 305 307 305 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 558 560 558 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 582 584 582 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 701 703 701 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 725 727 725 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 997 999 997 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1016 1018 1016 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1129 1131 1129 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3E</xref>
###xml 1136 1138 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3F</xref>
###xml 1269 1274 1269 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A&#8211;3F</xref>
###xml 1465 1466 1465 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 1226 1230 <span type="species:ncbi:10090">mice</span>
###xml 1297 1301 <span type="species:ncbi:10090">mice</span>
###xml 1611 1615 <span type="species:ncbi:10090">mice</span>
Consistent with previous studies [31], mechanical allodynia and thermal hyperalgesia developed after morphine withdrawal in the WT mice that received repeated injections of s.c. morphine plus i.p. saline (Fig. 3). Paw withdrawal frequencies were significantly increased by 3 fold (P < 0.01) and 2.8 fold (P < 0.01) from baseline on left and right hind paws, respectively, in response to a low-intensity mechanical stimulation (0.24 mN) on day 1 after morphine withdrawal (Fig. 3A and 3B). Paw withdrawal frequencies were also markedly increased by 2.9 fold (P < 0.01) and 2.4 fold (P < 0.01) from baseline on left and right hind paws, respectively, on day 1 after morphine withdrawal and by 2.4 fold (P < 0.01) and 2.1 fold (P < 0.01) from baseline on left and right hind paws, respectively, on day 2 after morphine withdrawal in response to a moderate mechanical stimulation (1.47 mN; Fig. 3C and 3D). Paw withdrawal latencies in response to heat stimulation were significantly decreased by 27% (P < 0.05) and 32% (P < 0.05) from the baseline on left and right hind paws, respectively, on day 1 after morphine withdrawal (Figs. 3E and 3F). Both mechanical allodynia and thermal hyperalgesia were completely blocked in the WT mice that also received i.p. MK-801 (Figs. 3A-3F). In contrast, the KO mice that received repeated injections of s.c. morphine plus i.p. saline or MK-801 did not exhibit significant changes in paw withdrawal frequencies or latencies (Fig. 3). In addition, repeated injections of i.p. MK-801 at the dose used did not affect basal paw withdrawal frequency and latency in either WT or KO mice that received s.c saline (data not shown).
###end p 36
###begin p 37
###xml 0 128 0 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of targeted disruption of PSD-93 gene on mechanical allodynia and thermal hyperalgesia after repeated morphine injection.</bold>
###xml 493 495 493 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 502 505 502 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 670 672 670 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 679 682 679 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
Effect of targeted disruption of PSD-93 gene on mechanical allodynia and thermal hyperalgesia after repeated morphine injection. WT and PSD-93 KO mice were injected twice daily with subcutaneous morphine (M, 20 mg/kg) and once daily with intraperitoneal saline (S) or 0.3 mg/kg MK-801 for 6 days. (A-D) Withdrawal responses of left (A and C) and right (B and D) hind paws to 0.24 mN (A and B) and 1.47 mN (C and D) intensity mechanical stimuli on days 1, 2, and 4 after morphine withdrawal. **P < 0.01 vs the corresponding baseline. (E and F) Withdrawal response of left (E) and right (F) hind paws to thermal stimulation on days 1, 2, and 4 after morphine withdrawal. *P < 0.05 vs the corresponding baseline.
###end p 37
###begin p 38
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 574 576 574 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 698 700 698 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 717 719 717 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 913 914 913 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 658 662 <span type="species:ncbi:10090">mice</span>
###xml 784 788 <span type="species:ncbi:10090">mice</span>
###xml 902 906 <span type="species:ncbi:10090">mice</span>
We also examined whether PSD-93 deletion affected morphine-induced behavioral sensitivity in response to formalin-induced noxious inflammation [26,31]. As expected, an intraplantar injection of 1% formalin produced characteristic biphasic licking behaviors in the mice (Fig. 4A). The first phase behavioral response of the formalin test was similar in all groups of WT and KO mice (Fig. 4). The second phase response was greatly enhanced in the morphine-treated WT mice (Fig. 4). Duration of paw licking was increased by 1.8 fold of the value in the saline-treated WT mice (P < 0.01). However, durations of paw licking in the saline- and morphine-treated KO mice were significantly reduced by 47% (P < 0.01) and 39% (P < 0.01), respectively, compared to that in the saline-treated WT mice. No significant difference was observed in the second phase response between the saline- and morphine-treated KO mice (Fig. 4).
###end p 38
###begin p 39
###xml 0 188 0 188 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Formalin-induced licking behaviors on day 1 after morphine withdrawal in WT and KO mice that received subcutaneous injections of 20 mg/kg morphine (M) or saline (S) twice daily for 6 days.</bold>
###xml 245 247 245 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 259 261 259 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 268 271 268 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 411 413 411 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 420 423 420 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
Formalin-induced licking behaviors on day 1 after morphine withdrawal in WT and KO mice that received subcutaneous injections of 20 mg/kg morphine (M) or saline (S) twice daily for 6 days. (A) Time course of formalin-induced licking behaviors. *P < 0.05 or **P < 0.01 vs the values in the saline-treated WT mice at the corresponding time point. (B) Summary of licking duration in the first and second phases. **P < 0.01 vs the saline-treated WT mice in the second phase.
###end p 39
###begin title 40
3.4. Effect of PSD-93 deletion on naloxone-induced withdrawal symptoms
###end title 40
###begin p 41
###xml 34 35 34 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 36 38 36 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 315 317 315 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 587 589 587 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
Consistent with previous studies [8,27], repeated injections of s.c. morphine plus i.p. saline produced striking jumping activity, one of naloxone-precipitated withdrawal symptoms, in the WT mice (Fig. 5). This jumping activity was significantly blocked in the WT mice that received s.c. morphine plus i.p. MK-801 (P < 0.01; Fig. 5). The KO mice that received repeated injections of s.c. morphine plus i.p. saline or MK-801 jumped significantly less than the WT mice (Fig. 5). The number of jumps was 98.5% less in the KO than in the WT mice that received s.c morphine plus i.p. saline (P < 0.01).
###end p 41
###begin p 42
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of targeted disruption of PSD-93 gene on physical dependence induced by repeated morphine injections.</bold>
###xml 459 461 459 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 468 471 468 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
Effect of targeted disruption of PSD-93 gene on physical dependence induced by repeated morphine injections. WT and KO mice were given morphine injections (10 mg/kg, s.c.) twice daily for 6 days plus a once-daily intraperitoneal injection of either saline or 0.3 mg/kg MK-801. Bars represent mean number of jumps in the 15-min period following a single naloxone injection (2 mg/kg) that was given 2 h after a final 10-mg/kg subcutaneous morphine injection. **P < 0.01 vs the saline + morphine group.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 174 183 174 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 684 693 684 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1331 1333 1331 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1628 1630 1628 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1631 1633 1631 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
###xml 1140 1144 <span type="species:ncbi:10090">mice</span>
###xml 1808 1812 <span type="species:ncbi:10090">mice</span>
An important observation in the present study is that PSD-93 deficiency produces distinct effects on synaptic NMDAR expression in different regions of the CNS. Evidence from in vitro studies shows that PSD-93 clusters and anchors NMDARs at synapses through interaction of its PDZ domains with seven C-terminal amino acids of NR2A and NR2B [9,10]. Our quantitative Western blot analysis showed that PSD-93 deficiency significantly reduced the levels of NR2A and NR2B proteins in the synaptosomal membrane fractions of dorsal horn and forebrain cortex but did not affect their expression in the total soluble fractions of these two regions. This finding is consistent with our previous in vitro study, which showed that surface NR2A and NR2B expression is dramatically reduced in cultured dorsal horn neurons of KO mice [16]. The data suggest that PSD-93 is required for synaptic expression and localization of NR2A and NR2B in dorsal horn and forebrain cortex. However, PSD-93 deficiency did not markedly change the amounts of NR2A and NR2B in either synaptosomal or total soluble fractions from cerebellum. Hippocampus neurons in PSD-93 KO mice may also express normal levels of NR2A and NR2B at synapses because PSD-93 deletion does not alter NMDAR-mediated excitatory postsynaptic currents and potentials in hippocampus neurons [17]. It appears that the effect of PSD-93 deletion on NR2A and NR2B synaptic expression may be tissue specific in the CNS, although the detailed mechanisms underlying these events are still unclear. PSD-95 and SAP102, two members of the MAGUK family of proteins, also interact with NR2A and NR2B [13,32]. It is very likely that PSD-95 and SAP102 compensate for the deficiency of PSD-93 to anchor and target NMDARs at synapses in hippocampus and cerebellum neurons of PSD-93 KO mice.
###end p 44
###begin p 45
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 714 721 714 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1123 1125 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1525 1526 1525 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1527 1528 1527 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1887 1889 1887 1889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1985 1987 1985 1987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 2137 2139 2137 2139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 859 863 <span type="species:ncbi:10090">mice</span>
###xml 901 905 <span type="species:ncbi:10090">mice</span>
###xml 1641 1645 <span type="species:ncbi:10090">mice</span>
Spinal cord and forebrain cortex are two major pain-related regions in the CNS [18,19]. Our previous studies demonstrated that PSD-93, NR2A, and NR2B are highly expressed in the superficial dorsal horn of spinal cord [16]. Under electron microscopy, the sections from superficial dorsal horn and the anterior cingular cortex of forebrain exhibited double labeling for PSD-93 and NR2A/NR2B in the postsynaptic density [16]. Furthermore, by co-immunoprecipitation, we found that both NR2A and NR2B were immunopreciptated by PSD-93 antibody in the postsynaptic density fractions of the spinal cord and forebrain cortex [16]. These findings demonstrate PSD-93 binding to NMDARs in the spinal cord and forebrain cortex in vivo. Electrophysiological recordings showed that PSD-93 deletion reduced NMDAR-mediated postsynaptic responses in these two regions of adult mice [16]. Behavioral study revealed that mice lacking PSD-93 exhibited blunted NMDAR-dependent persistent pain induced by peripheral nerve injury or injection of Complete Freund's Adjuvant, although they displayed intact nociceptive responsiveness to acute pain [16]. The present study showed that PSD-93 deficiency significantly inhibited acute and chronic morphine analgesic tolerance, enhancing formalin-induced pain behaviors, and withdrawal-induced jumping following repeated morphine injection. Morphine-induced tolerance, abnormal pain hypersensitivity, and physical dependence are considered to be related to NMDAR-dependent neuronal plasticity in the CNS [6-8]. Thus, it is very likely that these impaired morphine analgesic tolerance and physical dependence in PSD-93 KO mice is attributed to PSD-93 deletion-induced reduction in postsynaptic expression and function of NMDARs in dorsal horn and forebrain cortex neurons. Hippocampal NMDARs play a critical role in neuronal plasticity underlying learning and memory [33], whereas cerebellar NMDARs are involved in the modulation of motor learning and coordination [20]. Because PSD-93 deletion does not affect synaptic NMDAR expression and NMDAR-mediated postsynaptic functions in these two non-pain-related regions [17], PSD-93 deletion does not produce hippocampal and cerebellar dysfunctions, but does attenuate the development of persistent pain and morphine tolerance and physical dependence. Thus, targeted disruption of PSD-93 or perturbing NMDAR-PSD-93 interaction might be a better strategy for prevention and/or treatment of persistent pain and opioid tolerance and physical dependence in clinic.
###end p 45
###begin p 46
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1094 1095 1094 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1106 1108 1102 1104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1129 1131 1125 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1177 1179 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1180 1182 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 981 985 <span type="species:ncbi:10090">mice</span>
It should be noted that PSD-93 also functions as a scaffolding protein to assemble a specific set of signaling proteins around the NMDARs. These signaling proteins, such as neuronal nitric oxide (NO) synthase (nNOS), participate in downstream signaling by the NMDARs. The PDZ domain of nNOS interacts with the PDZ domains of PSD-93 [9]. Deleting the PDZ domain from PSD-93 reduces NOS activity [9]. Our previous study showed that targeted disruption of PSD-93 gene significantly attenuates the NMDA-stimulated increase in cyclic guanosine 3', 5'-monophosphate in the cultured forebrain cortex neurons [30]. Given that inhibition of nNOS attenuates the development of persistent pain and morphine analgesic tolerance and physical dependence [34,35], it is very likely that the dissociation of NMDARs from NO signaling caused by PSD-93 deletion is also involved in the mechanism underlying impairing persistent pain and morphine analgesic tolerance and physical dependence in the KO mice. Besides NMDARs and nNOS, PSD-93 binds to other postsynaptic membrane proteins, such as potassium channels [9,10], delta2 glutamate receptors [36], and the microtubule-associated protein 1A [36,37]. Therefore, the detailed mechanism through which PSD-93 deficiency affects the development of neuronal plasticity in persistent pain and morphine tolerance and physical dependence remains to be explored.
###end p 46
###begin p 47
###xml 240 244 <span type="species:ncbi:10090">mice</span>
In conclusion, the present study was the first to demonstrate that PSD-93 deletion has distinct effects on synaptic NMDAR expression in the CNS. Blunted NMDAR-dependent neuronal plasticity following repeated morphine injection in PSD-93 KO mice is attributed to PSD-93 deletion-induced alterations of NR2A and NR2B postsynaptic expression in dorsal horn and forebrain cortex neurons, but not in cerebellar neurons. Our findings suggest that PSD-93 might be a potential biochemical target for the treatment of opioid tolerance and physical dependence.
###end p 47
###begin title 48
Competing interests
###end title 48
###begin p 49
The authors declare that they have no competing interests.
###end p 49
###begin title 50
Acknowledgements
###end title 50
###begin p 51
###xml 202 206 <span type="species:ncbi:10090">mice</span>
This work was supported by NIH Grants NS 058886 and NS 057343 and the Johns Hopkins University Blaustein Pain Research Fund (Y.X.T.). The authors thank Dr. David S. Bredt for kindly providing PSD-93 KO mice and Claire Levine, MS, for her editorial assistance.
###end p 51
###begin article-title 52
Opioid complications and side effects
###end article-title 52
###begin article-title 53
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Addiction, physical dependence, and tolerance: precise definitions to help clinicians evaluate and treat chronic pain patients
###end article-title 53
###begin article-title 54
Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence
###end article-title 54
###begin article-title 55
Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal
###end article-title 55
###begin article-title 56
Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization
###end article-title 56
###begin article-title 57
Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions
###end article-title 57
###begin article-title 58
Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies
###end article-title 58
###begin article-title 59
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Locus-specific rescue of GluRepsilon1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence
###end article-title 59
###begin article-title 60
Cloning and characterization of postsynaptic density 93, a nitric oxide synthase interacting protein
###end article-title 60
###begin article-title 61
Heteromultimerization and NMDA receptor-clustering activity of Chapsyn-110, a member of the PSD-95 family of proteins
###end article-title 61
###begin article-title 62
###xml 4 7 <span type="species:ncbi:10116">rat</span>
###xml 70 80 <span type="species:ncbi:7227">Drosophila</span>
The rat brain postsynaptic density fraction contains a homolog of the Drosophila discs-large tumor suppressor protein
###end article-title 62
###begin article-title 63
###xml 9 12 <span type="species:ncbi:10116">rat</span>
###xml 63 73 <span type="species:ncbi:7227">Drosophila</span>
SAP90, a rat presynaptic protein related to the product of the Drosophila tumor suppressor gene dlg-A
###end article-title 63
###begin article-title 64
Interaction of the N-methyl-D-aspartate receptor complex with a novel synapse-associated protein, SAP102
###end article-title 64
###begin article-title 65
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 65 75 <span type="species:ncbi:7227">Drosophila</span>
Cloning and characterization of hdlg: the human homologue of the Drosophila discs large tumor suppressor binds to protein 4.1
###end article-title 65
###begin article-title 66
###xml 118 128 <span type="species:ncbi:7227">Drosophila</span>
Molecular characterization and spatial distribution of SAP97, a novel presynaptic protein homologous to SAP90 and the Drosophila discs-large tumor suppressor protein
###end article-title 66
###begin article-title 67
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Impaired NMDA receptor-mediated postsynaptic function and blunted NMDA receptor-dependent persistent pain in mice lacking postsynaptic density-93 protein
###end article-title 67
###begin article-title 68
Synapse-specific and developmentally regulated targeting of AMPA receptors by a family of MAGUK scaffolding proteins
###end article-title 68
###begin article-title 69
The neuropathic pain triad: neurons, immune cells and glia
###end article-title 69
###begin article-title 70
A synaptic model for pain: long-term potentiation in the anterior cingulate cortex
###end article-title 70
###begin article-title 71
Cerebellar neurocognition: Insights into the bottom of the brain
###end article-title 71
###begin article-title 72
###xml 17 21 <span type="species:ncbi:10090">mice</span>
PSD-93 knock-out mice reveal that neuronal MAGUKs are not required for development or function of parallel fiber synapses in cerebellum
###end article-title 72
###begin article-title 73
###xml 170 174 <span type="species:ncbi:10090">mice</span>
Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice
###end article-title 73
###begin article-title 74
Intrathecal Zn2+ attenuates morphine antinociception and the development of acute tolerance
###end article-title 74
###begin article-title 75
The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids
###end article-title 75
###begin article-title 76
Effect of genetic knockout or pharmacologic inhibition of neuronal nitric oxide synthase on complete Freund's adjuvant-induced persistent pain
###end article-title 76
###begin article-title 77
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice
###end article-title 77
###begin article-title 78
###xml 54 59 <span type="species:ncbi:10090">mouse</span>
Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence
###end article-title 78
###begin article-title 79
Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane
###end article-title 79
###begin article-title 80
Biochemical and morphological characterization of an intracellular membrane compartment containing AMPA receptors
###end article-title 80
###begin article-title 81
Targeted disruption of PSD-93 gene reduces platelet-activating factor-induced neurotoxicity in cultured cortical neurons
###end article-title 81
###begin article-title 82
###xml 2 8 <span type="species:ncbi:10090">murine</span>
A murine model of opioid-induced hyperalgesia
###end article-title 82
###begin article-title 83
Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95
###end article-title 83
###begin article-title 84
Molecular mechanisms of the alterations in NMDA receptor-dependent long-term potentiation in hyperammonemia
###end article-title 84
###begin article-title 85
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Effect of 7-nitroindazole on tolerance to morphine, U-50,488H and [D-Pen2, D-Pen5] enkephalin in mice
###end article-title 85
###begin article-title 86
Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal
###end article-title 86
###begin article-title 87
Postsynaptic density-93 interacts with the delta2 glutamate receptor subunit at parallel fiber synapses
###end article-title 87
###begin article-title 88
Localization of postsynaptic density-93 to dendritic microtubules and interaction with microtubule-associated protein 1A
###end article-title 88

